DIANTHUS THERAPEUTICS, INC.

Analyst Reco. Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2024-09-12			5-day change	1st Jan Change
27.81 ^USD	+0.87%		+4.47%	+167.40%

Aug. 09	Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	MT
Aug. 08	Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	Aug. 09	MT
Baird Starts Dianthus Therapeutics With Outperform Rating, $58 Price Target	Jul. 26	MT
Cantor Fitzgerald Initiates Dianthus Therapeutics at Overweight	Jun. 27	MT
HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target	May. 16	MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating	May. 10	MT
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating	Mar. 22	MT
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target	Feb. 15	MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating	Jan. 26	MT
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target	Dec. 26	MT
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate	Nov. 22	MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target	23-09-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!

BENEFIT NOW